114 related articles for article (PubMed ID: 10629551)
1. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer.
Gee JM; Robertson JF; Ellis IO; Nicholson RI; Hurst HC
J Pathol; 1999 Dec; 189(4):514-20. PubMed ID: 10629551
[TBL] [Abstract][Full Text] [Related]
2. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
[TBL] [Abstract][Full Text] [Related]
3. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Esteva FJ; Sahin AA; Rassidakis GZ; Yuan LX; Smith TL; Yang Y; Gilcrease MZ; Cristofanilli M; Nahta R; Pusztai L; Claret FX
Clin Cancer Res; 2003 Nov; 9(15):5652-9. PubMed ID: 14654548
[TBL] [Abstract][Full Text] [Related]
4. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression?
Woenckhaus C; Giebel J; Failing K; Fenic I; Dittberner T; Poetsch M
J Pathol; 2003 Oct; 201(2):278-87. PubMed ID: 14517845
[TBL] [Abstract][Full Text] [Related]
5. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of activator protein-2 isoforms in renal cell carcinoma.
Oya M; Mikami S; Mizuno R; Miyajima A; Horiguchi Y; Nakashima J; Marumo K; Mukai M; Murai M
Urology; 2004 Jul; 64(1):162-7. PubMed ID: 15245963
[TBL] [Abstract][Full Text] [Related]
7. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.
Pellikainen J; Kataja V; Ropponen K; Kellokoski J; Pietiläinen T; Böhm J; Eskelinen M; Kosma VM
Clin Cancer Res; 2002 Nov; 8(11):3487-95. PubMed ID: 12429639
[TBL] [Abstract][Full Text] [Related]
8. Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer.
Ruiz M; Troncoso P; Bruns C; Bar-Eli M
Clin Cancer Res; 2001 Dec; 7(12):4086-95. PubMed ID: 11751506
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival.
Gee JM; Eloranta JJ; Ibbitt JC; Robertson JF; Ellis IO; Williams T; Nicholson RI; Hurst HC
J Pathol; 2009 Jan; 217(1):32-41. PubMed ID: 18825690
[TBL] [Abstract][Full Text] [Related]
10. Expression of p27kip1 in breast cancer and its prognostic significance.
Barnes A; Pinder SE; Bell JA; Paish EC; Wencyk PM; Robertson JF; Elston CW; Ellis IO
J Pathol; 2003 Nov; 201(3):451-9. PubMed ID: 14595757
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
el-A Helal T; Khalifa A; Kamel AS
Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
[TBL] [Abstract][Full Text] [Related]
12. Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer.
Anttila MA; Kellokoski JK; Moisio KI; Mitchell PJ; Saarikoski S; Syrjänen K; Kosma VM
Br J Cancer; 2000 Jun; 82(12):1974-83. PubMed ID: 10864206
[TBL] [Abstract][Full Text] [Related]
13. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
14. Concordant loss of fragile gene expression early in breast cancer development.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast.
Wong SC; Chan JK; Lee KC; Hsiao WL
J Pathol; 2001 May; 194(1):35-42. PubMed ID: 11329139
[TBL] [Abstract][Full Text] [Related]
16. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the human activator protein-2gamma (AP-2gamma) gene: control of expression by Sp1/Sp3 in breast tumour cells.
Hasleton MD; Ibbitt JC; Hurst HC
Biochem J; 2003 Aug; 373(Pt 3):925-32. PubMed ID: 12733991
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer.
Gery S; Tanosaki S; Bose S; Bose N; Vadgama J; Koeffler HP
Clin Cancer Res; 2005 May; 11(9):3184-90. PubMed ID: 15867211
[TBL] [Abstract][Full Text] [Related]
19. Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis.
Rakha EA; Pinder SE; Paish EC; Robertson JF; Ellis IO
J Pathol; 2004 Jul; 203(3):754-61. PubMed ID: 15221934
[TBL] [Abstract][Full Text] [Related]
20. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]